![]() |
![]() | ![]() |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
Gentlemen and ladies of course... It was time that someone reflected on Genzyme's low price and made a speculation about possible future growth. I have been familar with the company for several years and have ridin in previous upwings. This company is a monopoly supplier of Glucocerbrosidase - the excruciatingly expensive treatment for Gaucher disease. This company is big... I am curious whether anyone values a call option play on this company in the near future. Sincerely, Antal | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |